Last10K.com

Esperion Therapeutics, Inc. (ESPR) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Esperion Therapeutics, Inc.

CIK: 1434868 Ticker: ESPR
Document and Entity Information (USD $)
In Millions, except Share data, unless otherwise specified
0 Months Ended 12 Months Ended
Mar. 01, 2014
Dec. 31, 2013
Jul. 02, 2013
Document and Entity Information      
Entity Registrant Name   Esperion Therapeutics, Inc.  
Entity Central Index Key   0001434868  
Document Type   10-K  
Document Period End Date   Dec. 31, 2013  
Amendment Flag   false  
Current Fiscal Year End Date   --12-31  
Entity Well-known Seasoned Issuer   No  
Entity Voluntary Filers   No  
Entity Current Reporting Status   Yes  
Entity Filer Category   Non-accelerated Filer  
Entity Public Float     $ 204.6
Entity Common Stock, Shares Outstanding 15,394,226    
Document Fiscal Year Focus   2013  
Document Fiscal Period Focus   FY  
Entity Listing, Par Value Per Share $ 0.001    

View differences made from one year to another to evaluate Esperion Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Esperion Therapeutics, Inc..

Continue

Assess how Esperion Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Esperion Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Balance Sheets
Balance Sheets (parenthetical)
Statements Of Cash Flows
Statements Of Cash Flows (parenthetical)
Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit)
Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit) (parenthetical 2)
Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit) (parenthetical)
Statements Of Operations And Comprehensive Loss
Commitments And Contingencies
Commitments And Contingencies (details 2)
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Convertible Preferred Stock And Stockholders' Deficit
Convertible Preferred Stock And Stockholders' Deficit (details)
Convertible Preferred Stock And Stockholders' Deficit (tables)
Debt
Debt (details 2)
Debt (details)
Debt (tables)
Employee Benefit Plan
Employee Benefit Plan (details)
Fair Value Measurements
Fair Value Measurements (details 2)
Fair Value Measurements (details 3)
Fair Value Measurements (details)
Fair Value Measurements (tables)
Income Taxes
Income Taxes (details 2)
Income Taxes (details 3)
Income Taxes (details)
Income Taxes (tables)
Investments
Investments (details)
Investments (tables)
License Agreement
License Agreement (details)
Net Loss Per Common Share
Net Loss Per Common Share (details)
Net Loss Per Common Share (tables)
Other Accrued Liabilities
Other Accrued Liabilities (details)
Other Accrued Liabilities (tables)
Property And Equipment
Property And Equipment (details)
Property And Equipment (tables)
Selected Quarterly Financial Data (unaudited)
Selected Quarterly Financial Data (unaudited) (details)
Selected Quarterly Financial Data (unaudited) (tables)
Stock Acquisition
Stock Acquisition (details)
Stock Acquisition (tables)
Stock Compensation
Stock Compensation (details)
Stock Compensation (tables)
Subsequent Events
Subsequent Events (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
The Company And Basis Of Presentation
The Company And Basis Of Presentation (details 2)
The Company And Basis Of Presentation (details)
The Company And Basis Of Presentation (tables)
Warrants
Warrants (details)

Material Contracts, Statements, Certifications & more

Esperion Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ESPR
CIK: 1434868
Form Type: 10-K Annual Report
Accession Number: 0001047469-14-002320
Submitted to the SEC: Thu Mar 13 2014 4:05:08 PM EST
Accepted by the SEC: Thu Mar 13 2014
Period: Tuesday, December 31, 2013
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/espr/0001047469-14-002320.htm